Clinical Trial Update: High-Dose Intravenous Interleukin-2 in Treating Patients With Metastatic Renal Cell Carcinoma (Kidney Cancer) That Has Not Responded to Previous Low-Dose Intravenous or Subcutaneous Interleukin-2 [Phase 2]

View source ↗

Summary

A Phase 2 study assessing high-dose intravenous interleukin-2 in patients with metastatic renal cell carcinoma that did not respond to prior low-dose IL-2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Interleukin-2 (Aldesleukin) (aldesleukin)

Snippet

Sponsor: Blumenthal Cancer Center at Carolinas Medical Center | Conditions: Kidney Cancer | Phase 2 | Status: UNKNOWN